Basilea Pharmaceutica (OTCMKTS:BPMUF) Downgraded by Zacks Investment Research


Share on StockTwits

Zacks Investment Research downgraded shares of Basilea Pharmaceutica (OTCMKTS:BPMUF) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. “

OTCMKTS BPMUF opened at $50.20 on Thursday. The stock has a market capitalization of $539.18 million, a PE ratio of -24.02 and a beta of 1.50. The business has a 50 day simple moving average of $51.00 and a two-hundred day simple moving average of $55.87. Basilea Pharmaceutica has a 1-year low of $49.00 and a 1-year high of $61.00.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally, as well as in Phase III clinical trials for invasive fungal infections in Japan.

Recommended Story: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Basilea Pharmaceutica (BPMUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.